|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NFKBIL1 |
Gene summary for NFKBIL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NFKBIL1 | Gene ID | 4795 |
| Gene name | NFKB inhibitor like 1 | |
| Gene Alias | IKBL | |
| Cytomap | 6p21.33 | |
| Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | A0A0A0MRT5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4795 | NFKBIL1 | LZE4T | Human | Esophagus | ESCC | 1.52e-11 | 1.68e-01 | 0.0811 |
| 4795 | NFKBIL1 | LZE7T | Human | Esophagus | ESCC | 1.16e-08 | 3.48e-01 | 0.0667 |
| 4795 | NFKBIL1 | LZE8T | Human | Esophagus | ESCC | 3.36e-02 | 1.17e-01 | 0.067 |
| 4795 | NFKBIL1 | LZE20T | Human | Esophagus | ESCC | 4.50e-08 | 2.39e-01 | 0.0662 |
| 4795 | NFKBIL1 | LZE22T | Human | Esophagus | ESCC | 1.73e-03 | 3.06e-01 | 0.068 |
| 4795 | NFKBIL1 | LZE24T | Human | Esophagus | ESCC | 1.20e-24 | 6.35e-01 | 0.0596 |
| 4795 | NFKBIL1 | LZE22D3 | Human | Esophagus | HGIN | 4.70e-03 | 5.02e-01 | 0.0653 |
| 4795 | NFKBIL1 | LZE6T | Human | Esophagus | ESCC | 4.74e-03 | 2.28e-01 | 0.0845 |
| 4795 | NFKBIL1 | P1T-E | Human | Esophagus | ESCC | 5.38e-10 | 4.87e-01 | 0.0875 |
| 4795 | NFKBIL1 | P2T-E | Human | Esophagus | ESCC | 7.18e-32 | 5.29e-01 | 0.1177 |
| 4795 | NFKBIL1 | P4T-E | Human | Esophagus | ESCC | 1.43e-29 | 6.31e-01 | 0.1323 |
| 4795 | NFKBIL1 | P5T-E | Human | Esophagus | ESCC | 6.38e-27 | 4.32e-01 | 0.1327 |
| 4795 | NFKBIL1 | P8T-E | Human | Esophagus | ESCC | 2.74e-15 | 2.16e-01 | 0.0889 |
| 4795 | NFKBIL1 | P9T-E | Human | Esophagus | ESCC | 1.36e-14 | 2.31e-01 | 0.1131 |
| 4795 | NFKBIL1 | P10T-E | Human | Esophagus | ESCC | 1.14e-23 | 5.09e-01 | 0.116 |
| 4795 | NFKBIL1 | P11T-E | Human | Esophagus | ESCC | 1.65e-16 | 5.58e-01 | 0.1426 |
| 4795 | NFKBIL1 | P12T-E | Human | Esophagus | ESCC | 3.95e-24 | 4.28e-01 | 0.1122 |
| 4795 | NFKBIL1 | P15T-E | Human | Esophagus | ESCC | 3.73e-16 | 3.08e-01 | 0.1149 |
| 4795 | NFKBIL1 | P16T-E | Human | Esophagus | ESCC | 2.83e-27 | 5.83e-01 | 0.1153 |
| 4795 | NFKBIL1 | P17T-E | Human | Esophagus | ESCC | 3.71e-21 | 5.14e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000724918 | Esophagus | HGIN | I-kappaB kinase/NF-kappaB signaling | 67/2587 | 281/18723 | 3.84e-06 | 1.29e-04 | 67 |
| GO:00028325 | Esophagus | HGIN | negative regulation of response to biotic stimulus | 25/2587 | 108/18723 | 5.87e-03 | 4.77e-02 | 25 |
| GO:000724919 | Esophagus | ESCC | I-kappaB kinase/NF-kappaB signaling | 183/8552 | 281/18723 | 3.02e-11 | 1.01e-09 | 183 |
| GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
| GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
| GO:000283212 | Esophagus | ESCC | negative regulation of response to biotic stimulus | 72/8552 | 108/18723 | 8.36e-06 | 8.11e-05 | 72 |
| GO:003249619 | Esophagus | ESCC | response to lipopolysaccharide | 191/8552 | 343/18723 | 1.11e-04 | 7.73e-04 | 191 |
| GO:000223719 | Esophagus | ESCC | response to molecule of bacterial origin | 194/8552 | 363/18723 | 1.64e-03 | 7.61e-03 | 194 |
| GO:00434332 | Esophagus | ESCC | negative regulation of DNA-binding transcription factor activity | 103/8552 | 185/18723 | 3.86e-03 | 1.57e-02 | 103 |
| GO:007122215 | Esophagus | ESCC | cellular response to lipopolysaccharide | 113/8552 | 209/18723 | 8.79e-03 | 3.10e-02 | 113 |
| GO:00316633 | Esophagus | ESCC | lipopolysaccharide-mediated signaling pathway | 37/8552 | 60/18723 | 9.17e-03 | 3.19e-02 | 37 |
| GO:007121617 | Esophagus | ESCC | cellular response to biotic stimulus | 131/8552 | 246/18723 | 9.85e-03 | 3.39e-02 | 131 |
| GO:00320882 | Esophagus | ESCC | negative regulation of NF-kappaB transcription factor activity | 54/8552 | 93/18723 | 1.08e-02 | 3.67e-02 | 54 |
| GO:00072494 | Liver | Cirrhotic | I-kappaB kinase/NF-kappaB signaling | 108/4634 | 281/18723 | 2.21e-07 | 5.64e-06 | 108 |
| GO:00324966 | Liver | Cirrhotic | response to lipopolysaccharide | 111/4634 | 343/18723 | 8.15e-04 | 5.95e-03 | 111 |
| GO:0002832 | Liver | Cirrhotic | negative regulation of response to biotic stimulus | 41/4634 | 108/18723 | 1.56e-03 | 1.01e-02 | 41 |
| GO:00022376 | Liver | Cirrhotic | response to molecule of bacterial origin | 113/4634 | 363/18723 | 3.23e-03 | 1.81e-02 | 113 |
| GO:00028311 | Liver | Cirrhotic | regulation of response to biotic stimulus | 101/4634 | 327/18723 | 6.58e-03 | 3.25e-02 | 101 |
| GO:00022211 | Liver | HCC | pattern recognition receptor signaling pathway | 107/7958 | 172/18723 | 1.37e-07 | 2.58e-06 | 107 |
| GO:000724912 | Liver | HCC | I-kappaB kinase/NF-kappaB signaling | 156/7958 | 281/18723 | 6.66e-06 | 8.00e-05 | 156 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NFKBIL1 | SNV | Missense_Mutation | novel | c.766N>C | p.Glu256Gln | p.E256Q | Q9UBC1 | protein_coding | tolerated(0.05) | probably_damaging(0.92) | TCGA-VS-A8QM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| NFKBIL1 | SNV | Missense_Mutation | c.434N>A | p.Gly145Glu | p.G145E | Q9UBC1 | protein_coding | tolerated(1) | benign(0.075) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| NFKBIL1 | SNV | Missense_Mutation | c.648G>T | p.Gln216His | p.Q216H | Q9UBC1 | protein_coding | tolerated(0.1) | benign(0.435) | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | |
| NFKBIL1 | SNV | Missense_Mutation | c.857N>G | p.Pro286Arg | p.P286R | Q9UBC1 | protein_coding | tolerated(0.5) | benign(0.197) | TCGA-F5-6863-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | etoposide | SD | |
| NFKBIL1 | SNV | Missense_Mutation | novel | c.368N>A | p.Arg123His | p.R123H | Q9UBC1 | protein_coding | tolerated(0.45) | benign(0.203) | TCGA-AP-A0LS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NFKBIL1 | SNV | Missense_Mutation | novel | c.172N>T | p.Gly58Cys | p.G58C | Q9UBC1 | protein_coding | deleterious(0.03) | possibly_damaging(0.68) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NFKBIL1 | SNV | Missense_Mutation | rs776864117 | c.653N>A | p.Arg218Gln | p.R218Q | Q9UBC1 | protein_coding | tolerated(0.38) | benign(0.005) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NFKBIL1 | SNV | Missense_Mutation | rs771750904 | c.610C>T | p.Arg204Cys | p.R204C | Q9UBC1 | protein_coding | tolerated(0.06) | benign(0.245) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NFKBIL1 | SNV | Missense_Mutation | rs544896018 | c.367N>T | p.Arg123Cys | p.R123C | Q9UBC1 | protein_coding | deleterious(0) | probably_damaging(0.921) | TCGA-D1-A176-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NFKBIL1 | SNV | Missense_Mutation | rs199596929 | c.772N>T | p.Arg258Cys | p.R258C | Q9UBC1 | protein_coding | tolerated(0.06) | benign(0.044) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4795 | NFKBIL1 | NA | IFN | 16362817 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |